Kallik Founder Recognised as One of Global Pharma Sectors Most Valuable Contributors
Labelling content and artwork management leader Kallik is delighted to announce that its founder and CEO Neil Gleghorn has just been recognised as one of the 100 most influential people on the global pharmaceutical stage.
The honour is confirmed by Neil being named to the landmark PharmaVOICE 100 List published by the sector’s leading independent editorial publication, PharmaVOICE.
Established 9 years ago, The PharmaVOICE 100 is an annual list of individuals determined by their peers as having made the most consistent, outstanding contribution to the life sciences industry, an industry whose UK representatives generate over £50 billion in sales every year according to government statistics.
According to the publishers, winners of PharmaVOICE 100 places illustrate what it means to think bigger, do more, and lead with passion and integrity, with all nominations decided by members of the sector.
“I am extremely honoured to receive this industry recognition,” said Neil.
“It is one of the most important peer awards in the pharmaceutical industry, and is testament to the work of everyone here at Kallik — not just me, but everyone from the most junior team member all the way up to the board, our partners and everyone who’s been part of the journey – and most important of all, our customers.”
A Long-Lasting Dialogue
Neil’s extensive knowledge and understanding of the pharma industry’s specific challenges was key to his winning a PharmaVOICE 100 place.
That is a knowledge base that he has used to develop forward-thinking solutions that help achieve efficiency and compliance as well as form the basis for on-going dialogues with customers about the long-term challenges they face.
“What a third party like a Kallik can do is see the gaps that siloed teams in procurement, regulatory or marketing in a pharmaceutical company just can’t,” he said. “We use that perspective to develop the kind of systems that the pharmaceutical companies of today are increasingly recognising as vital in maximising their opportunity in the market.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.